Not only that, studies have shown that EZH2 can also inhibit the expression of the immune checkpoint inhibitor PD-L1 by directly upregulating the levels of CD274 and IFN regulatory factor 1 (IRF1) promoter H3K27me3 in liver cancer cells [5]. Here, IRF1 is linked to liver cancer.